Survival rates for heart failure vary based on the stage of the condition, age at diagnosis, and response to treatment.
The average survival rates are:
1 Year: 87% 2 Years: 73% 5 Years: 57% 10 Years: 35%
Survival in heart failure remains poor despite therapeutic advances, with overall median survival of approximately 2-3 years after diagnosis and 5-year mortality rates of 50-75% depending on disease severity and ejection fraction subtype.
A patient’s outlook is heavily influenced by how advanced the heart failure is at the time of diagnosis:
Stages I & II (Mild): Many patients respond well to lifestyle changes and medication, often surviving 10 years or more.
Stage III (Moderate): Survival typ ically ranges between 5 to 10 years with treatments like pacemakers or defibrillators.
Stage IV (End-Stage): This is the most severe stage, with a median life expectancy often estimated at 6 to 12 months without advanced interventions.
Age at Diagnosis: Younger patients generally have much better survival rates. For those under 65, the 5-year survival rate is approximately 79%, compared to about 50% for those aged 75 and over.
Patients diagnosed as an outpatient often have better outcomes than those whose diagnosis requires immediate hospital admission.
Survival has improved significantly over the last few decades due to better medications and surgical options like heart transplants or LVADs..
Ejection Fraction (EF): While a normal EF is 55–70%, those with an EF under 40% may face a higher risk of complications, though some studies show similar overall survival across EF levels if managed correctly.
Present guideline-directed medical therapy (GDMT) has substantially improved outcomes, increasing life expectancy in heart failure with reduced ejection fraction (HFrEF) by up to three-fold, with a net gain of 8 years compared to conventional therapy.
Prognosis varies significantly by clinical context.
Patients hospitalized for acute heart failure have worse outcomes, with 1-year mortality of approximately 29-30%.
Among hospitalized patients, less than one in five survive to 10 years, with median survival of 2.8 years.
Advanced heart failure carries particularly grave prognosis,, and have 1-year mortality of approximately 50%, with median survival of 12 months.
For patients requiring continuous inotropic support, 1-year survival is only 6-11%.
5-year mortality is similarly poor across the ejection fraction spectrum—approximately 75% for HFrEF, heart failure with borderline ejection fraction (HFbEF), and heart failure with preserved ejection fraction (HFpEF).
All heart failure patients, regardless of ejection fraction, have markedly reduced median survival compared to age-matched general population controls.
Heart failure patients aged 65-69 years have median survival of only 4 years compared to 18.7 years expected in the general population.
Survival has improved modestly over recent decades.
Multiple factors influence survival in heart failure.
Age is a critical determinant—median survival declines progressively with advancing age at diagnosis.
Male sex is associated with worse prognosis.
Cardiovascular comorbidities including prior heart failure hospitalization, valvular disease and vascular disease predict higher mortality.
Non-cardiovascular comorbidities, particularly diabetes, chronic kidney odisease, and chronic lung disease, substantially increase excess lost life expectancy.
Hospitalization represents a major inflection point—patients not requiring admission at diagnosis have median survival 2.4 years longer than those hospitalized (5.3 vs 2.9 years).
Socioeconomic factors also matter, with a deprivation gap of 0.5 years in median survival between least and most deprived populations.
Elevated natriuretic peptides, hyponatremia, worsening renal function, and end-organ dysfunction all portend poor prognosis.
NT-proBNP levels below 1000 pg/mL suggest more benign course with fewer events.
Submaximal exercise testing and cognitive impairment also predict mortality.
Heart failure is associated with substantial loss of actuarially predicted life expectancy.
Compared to the general population, heart failure patients experience approximately 7.3 years of lost life expectancy (56.6% of expected life expectancy), with losses reaching 20.5 years for those aged 18-54 years.
Comorbidity accounts for the majority of this excess mortality.
Women without major comorbidity experience survival close to reference controls, while men still experience excess lost life even without comorbidity.